CD4 + cell

Related by string. CD4 + cells * CD4s : CD4 ^ sup . CD4 + CD# . CD4 + T lymphocytes . median CD4 . baseline CD4 . nadir CD4 cell / + - [008] . + - [003] . + - [027] . + - [020] . + - [007] . + - [017] : + S europe . + input switcher . Average + -1 . Crispin Porter + Bogusky . diagnosed Ph + / Cells . CELL . celled . Cell . CELLS : stem cell research . Q Cells AG . Q Cells SE . Fuel Cell . adult stem cells * *

Related by context. All words. (Click for frequent words.) 75 CD4 cell 75 baseline CD4 74 median CD4 72 CD4 + 72 HIV RNA 72 nadir CD4 cell 68 virologic failure 68 absolute lymphocyte 68 virologic response 67 baseline CD4 + 66 serum testosterone 66 cells uL 66 serum urate levels 66 cells mcL 65 neutrophil count 65 leukocyte count 65 specific antigen PSA 65 antibody titer 65 CD4 + T 64 granulocyte 64 lymphocyte counts 64 CD4 T 64 serum potassium 64 serum PSA 64 plasma leptin 64 neutrophil counts 64 glycosylated hemoglobin HbA1c 64 antiretroviral naive 64 lymphocyte count 63 HBeAg seroconversion 63 cells/mm3 63 serum uric acid 63 experienced virologic failure 63 serum concentrations 63 viral load 63 mg/m2 dose 63 HbA1C 63 HBV DNA 63 serum urate 63 ng dL 63 baseline HbA1c 63 aspartate aminotransferase AST 63 Hb A1C 63 serum creatinine levels 63 serum prostate 63 CD4 cells 63 glycated hemoglobin HbA1c 62 viremia 62 Inhibin B 62 tipranavir r 62 plasma uric acid 62 serum cortisol 62 serum phosphate levels 62 lactate dehydrogenase LDH 62 viral loads 62 serum HBV DNA 62 plasma folate 62 HBV DNA levels 62 HbA 1c levels 62 PSA nadir 62 LEXIVA r 62 follicle stimulating hormone FSH 62 serum phosphate 62 hemoglobin concentration 62 serum LDL cholesterol 62 serum calcium levels 62 doxorubicin docetaxel 62 insulin detemir 62 plasma renin activity 62 leukocytosis 62 reticulocytes 62 HCV RNA 62 antibody titers 62 CD4 + cells 61 hemoglobin Hb 61 thyroid stimulating hormone 61 lumbar spine BMD 61 undetectable viral load 61 triglyceride concentrations 61 oocytes retrieved 61 serum aminotransferase levels 61 platelet reactivity 61 anemia hemoglobin 61 virologic responses 61 aspartate aminotransferase 61 QTcF 61 cells μL 61 haematological toxicity 61 liver histology 61 urine albumin 61 leukocyte 61 hemoglobin A1c HbA1c 61 hematologic toxicity 61 plasma glucose 61 undetectable viral loads 61 alanine aminotransferase ALT 61 serum ALT 61 serum lipid levels 61 serum sodium 61 CD4 counts 61 paraprotein 61 NPH insulin 61 Viral load 61 log# copies mL 61 viral suppression 61 virological failure 61 BARACLUDE ® 60 virologic suppression 60 lopinavir r 60 alanine aminotransferase 60 CD4 60 troponin T 60 sustained virological response 60 hemoglobin A1c levels 60 plasma HCV RNA 60 relapsed MM 60 HbA1c levels 60 #mmHg [001] 60 AST ALT 60 iPTH 60 homocysteine concentrations 60 μmol L 60 thyrotropin 60 atazanavir ritonavir 60 fosamprenavir 60 albumin excretion 60 Cmax 60 serum IGF 60 inhibin 60 paricalcitol 60 IFN α 60 sustained virologic response 60 PREZISTA ritonavir 60 seroconversion 60 APTIVUS r 60 serum calcium 60 sUA 60 genotypic resistance 60 virologic 60 CsA 60 glomerular filtration 60 HER2 expression 60 virological response 60 Serum creatinine 60 antiretroviral naïve 60 antiandrogen 60 clodronate 60 hemoglobin concentrations 60 glycated hemoglobin levels 60 gliclazide 60 creatine kinase 60 comparator PI r 60 blood glucose concentrations 60 intraocular pressure IOP 60 Non inferiority 60 lopinavir r arm 60 blood Phe levels 60 pCR 60 HIV HCV coinfected 60 vicriviroc 60 HBsAg 60 hypogonadal 60 prospectively defined 60 lactate dehydrogenase 60 mg kg dose 60 CD# upregulation 60 HOMA IR 60 aminotransferases 60 PREZISTA r 60 ovarian carcinoma 59 thyroglobulin 59 CD4 lymphocyte count 59 severe neutropenia 59 urate lowering therapy 59 ritonavir boosted 59 serum vitamin D 59 platelet counts 59 glycemia 59 glycated hemoglobin 59 nelfinavir 59 #.#ng/ml 59 undetectable viral 59 prostate cancer CaP 59 triiodothyronine 59 undetectable HCV RNA 59 undetectable HBV DNA 59 inflammatory biomarkers 59 morphometric vertebral fractures 59 Subgroup analysis 59 LVEF 59 pg ml 59 viral titers 59 aminotransferase 59 ± SEM 59 lymphocytosis 59 mm ³ 59 β blockers 59 serum homocysteine 59 irbesartan 59 glomerular filtration rate 59 % CI #.#-#.# [003] 59 PSADT 59 motile sperm 59 BENICAR HCT 59 tipranavir ritonavir 59 systolic dysfunction 59 HbA 1c 59 serum phosphorus 59 intramuscular dose 59 biochemical relapse 59 REYATAZ r arm 59 fasting glucose levels 59 Primary endpoints 59 Ki# 59 abacavir lamivudine 59 NNRTI resistance 59 blood Phe 59 FOLPI 59 XIENCE V PROMUS Stent 59 serum folate 59 creatinine levels 59 mcg dose 59 rimonabant #mg 59 protein excretion 59 serum estradiol 59 β blocker 59 EDSS score 59 evaluable subjects 59 human chorionic gonadotropin hCG 59 umol L 59 ABC/3TC 59 GnRH agonist 59 IU mL 59 plasma triglycerides 59 serum albumin 59 bFGF 59 baseline LDH 59 urinary oxalate 59 plasma glucose levels 59 platelet aggregation 59 Kaplan Meier analysis 59 rFVIIa 59 pmol L 58 cytopenias 58 sperm motility 58 microliter 58 RBC folate 58 steroid dexamethasone 58 serum phosphorous 58 serum IgE 58 serum retinol 58 remission CR 58 serum triglycerides 58 mRS 58 octreotide LAR 58 platelet inhibition 58 serum glucose 58 recurrent VTE 58 virological suppression 58 Insulin sensitivity 58 CIMZIA TM 58 tipranavir 58 fasting plasma glucose FPG 58 thrombocytopenic 58 eosinophil count 58 plasma lipid 58 intravascular hemolysis 58 endometrial thickness 58 mL/min/#.# m 2 58 #.#/#.# mmHg [001] 58 seroprotection 58 Dose escalation 58 viraemia 58 TDF FTC 58 fructosamine 58 prospectively stratified 58 PAOD 58 urate levels 58 renal function 58 raltegravir 58 cytogenetic response 58 annualized relapse 58 mRCC 58 epithelial ovarian cancer 58 gout flares 58 antihypertensive therapy 58 plasma cortisol 58 galiximab 58 indinavir 58 #mg BID [003] 58 biochemical recurrence 58 autoantibody levels 58 Pred Forte 58 prolactin levels 58 Secondary efficacy endpoints 58 fasting plasma glucose 58 serum potassium levels 58 #mg/day [001] 58 darunavir 58 postoperative mortality 58 definite stent thrombosis 58 decitabine 58 CCyR 58 CD# + [002] 58 plasma concentrations 58 D dimer 58 eculizumab therapy 58 ALT flares 58 vWF 58 HBeAg positive 58 estimated glomerular filtration 58 trastuzumab Herceptin ® 58 SVR# 58 intima media thickness 58 lipid elevations 58 leukopenia 58 anti HBs 58 dose escalation phase 58 carotid IMT 58 transaminase levels 58 #mg dose [002] 58 mg BID 58 fasting triglycerides 58 dose cohort 58 pharmacodynamic effects 58 calculated creatinine clearance 58 serum clusterin levels 58 complete cytogenetic response 58 pulmonary capillary wedge 58 elevated LDH 58 Prostate Specific Antigen PSA 58 cART 58 Follicle Stimulating Hormone 58 intravenous dosing 58 ascending dose 58 microvessel density 58 concentration Cmax 58 NATRECOR R 58 glycosylated hemoglobin 58 apolipoprotein B 58 intact parathyroid hormone 58 Durezol 58 transgene expression 58 TMC# r 58 nmol liter 58 plasma pharmacokinetics 58 atheroma volume 58 leukocyte counts 58 PASI scores 58 circulating lymphocytes 58 CD4 + CD# 58 oral FTY# 58 SHBG levels 58 glycosylated hemoglobin levels 58 azacytidine 58 AZT zidovudine Retrovir 58 EDARBI 58 left ventricular systolic 57 lymphopenia 57 antigen PSA levels 57 FDA defined valvulopathy 57 CK MB 57 Elitek 57 leukemic cell 57 K#N 57 QTc 57 mcg BID 57 LPV r 57 mutated KRAS 57 DAPT 57 d4T stavudine Zerit 57 hydroxyvitamin D levels 57 euthyroid 57 nadolol 57 elevated troponin 57 ibandronate 57 CIN3 57 serum HCV RNA 57 6MWD 57 albumin excretion rate 57 mg ustekinumab 57 liver transplant recipients 57 CMV infection 57 serum cholesterol 57 lispro 57 pT3 57 proteinuria 57 teriflunomide 57 renal toxicity 57 comparator arm 57 LTB4 57 Decitabine 57 ATACAND 57 erythrocyte sedimentation rate 57 aPTT 57 Index CDAI 57 placebo dexamethasone 57 HbA1C levels 57 hematological parameters 57 log# reduction 57 dapagliflozin plus 57 seropositive patients 57 nonfasting triglyceride levels 57 achieved ACR# 57 calcitriol 57 nocturnal hypoglycaemia 57 corrected QT interval 57 beta blocker therapy 57 #.#/#.# mm Hg [003] 57 triglyceride concentration 57 antihypertensive medications 57 clinically meaningful improvement 57 protease inhibitor PI 57 PON1 enzyme 57 intermittent dosing 57 creatinine ratio 57 serum creatinine 57 elevated creatinine 57 bezafibrate 57 PCa 57 baseline A1C 57 serum testosterone levels 57 CR nPR 57 del 5q MDS 57 elevated ALT 57 enfuvirtide 57 IFN gamma 57 saquinavir 57 serum ferritin 57 anagrelide 57 pyrazinamide 57 corticosterone levels 57 MMSE score 57 Wistar rats 57 rFSH 57 Dasatinib 57 hemoglobin hematocrit 57 Intraocular pressure 57 liver enzymes ALT 57 mIU ml 57 timepoint 57 MELD scores 57 aminotransferase ALT 57 HBeAg 57 locomotor activity 57 circulating endothelial 57 Aptivus ® 57 flutamide 57 EDSS scores 57 lipoprotein Lp 57 #mg dose [001] 57 Akt activation 57 dosing cohort 57 intravaginal ejaculatory latency 57 histological subtype 57 5-FU/LV 57 hepatic fibrosis 57 -#.# log# copies mL 57 posttreatment 57 detectable HCV RNA 57 REYATAZ ® 57 μg ml 57 QTc intervals 57 APTIVUS 57 cabazitaxel 57 NNRTIs 57 A1c levels 57 heavily pretreated 57 lopinavir 57 dose ritonavir 57 pulmonary arterial 57 adjunctive placebo 57 mmHg systolic 57 timepoints 57 selenium supplementation 57 ertapenem 57 canakinumab 57 TNFalpha 57 nonrandomized 57 copies mL 57 darunavir r 57 aminotransferase levels 57 IELT 57 tolvaptan 57 #mg/m# [001] 57 magnesium intake 57 corticosteroid dose 57 mcg doses 57 eGFR 57 LHRH agonists 57 prostate specific 57 onset diabetes mellitus 57 -#.# log# 57 AZOR 57 recurrent glioblastoma multiforme 57 HIV uninfected 57 fasting glucose 57 fasting triglyceride levels 57 NIHSS 57 transaminase elevations 57 fasting blood glucose 57 NIHSS score 57 hsCRP levels 56 creatinine clearance 56 anti leukemic 56 proinflammatory cytokine 56 Lp PLA 2 56 extrapyramidal symptoms 56 riociguat 56 argatroban 56 adiponectin concentrations 56 lamivudine refractory patients 56 serum leptin 56 #mg/kg [002] 56 QTc interval 56 oxcarbazepine 56 CYP#D# genotype 56 fluvastatin 56 R0 resection 56 doxorubicin cyclophosphamide 56 CD4 + CD8 + 56 triacylglycerol 56 binary restenosis 56 ng dl 56 fasting insulin 56 HAQ DI 56 transdermal estradiol 56 dose cyclophosphamide 56 oxycodone CR 56 inotropic 56 Procoralan 56 dosing cohorts 56 SCIg 56 CrCl 56 elevated LDL cholesterol 56 serum antibody 56 mm Hg systolic 56 triacylglycerol concentrations 56 Diovan HCT 56 KRAS mutations 56 viral kinetics 56 exhaled nitric oxide 56 Triglyceride levels 56 adenoma recurrence 56 lumbar spine bone 56 urinary albumin 56 ISENTRESS 56 sUA levels 56 alteplase 56 HI titers 56 serum CRP 56 posttransplant 56 unboosted 56 Free Survival PFS 56 #.#mmHg 56 pg mL 56 HCV replicon 56 glulisine 56 P = .# 56 HBeAg negative 56 benazepril 56 RLAI 56 8mg/kg 56 PSA kinetics 56 posaconazole 56 tumor necrosis 56 Estradiol 56 urinary calcium 56 CANCIDAS 56 univariate analysis 56 multivariable analysis 56 amprenavir 56 copies ml 56 low dose cytarabine 56 preterm neonates 56 androgen therapy 56 #mg BID [001] 56 NHANES III 56 locoregional 56 ADAS cog 56 piperacillin tazobactam 56 SGPT 56 oral ibandronate 56 antidiabetic medication 56 #mg/day [002] 56 nucleotide analog 56 certolizumab 56 HCV RESPOND 2 56 #mmHg [002] 56 elevated transaminases 56 TPV r 56 serum bicarbonate 56 clomiphene citrate 56 HCV viral 56 genotype 1b 56 recurrent venous thromboembolism 56 osteoblast 56 adefovir 56 FOLFOX4 56 K ras mutations 56 Taxotere ® 56 rapid virological response 56 mammographic density 56 CPAP adherence 56 4mg/kg 56 nevirapine Viramune 56 Prostate Specific Antigen 56 plus dexamethasone 56 nonnucleoside reverse transcriptase inhibitors 56 moderate renal impairment 56 HAART regimen 56 μg L 56 dehydroepiandrosterone sulfate 56 hypogonadal men 56 ULORIC 56 divalproex sodium 56 hemodilution 56 TIMP 1 56 coadministration 56 preserved ejection fraction 56 arterial thickening 56 MULTAQ 56 Flu Cy 56 serum lipid 56 antiandrogens 56 edifoligide 56 atherogenic dyslipidemia 56 GnRH antagonist 56 mucosal healing 56 CMV disease 56 serum PTH 56 HGPIN 56 plasma glucose concentrations 56 mRNA expression 56 tHcy 56 GH secretion 56 chlamydial infection 56 hyperphenylalaninemia HPA due 56 Neutrophil 56 transaminases 56 oxycodone IR 56 daily subcutaneous injections 56 tryptase 56 pegylated liposomal doxorubicin 56 plasma renin 56 -#.# mg dL [002] 56 CCR5 tropic HIV 56 atherogenic lipids 56 plus methotrexate 56 interleukin IL -# 56 MAGE A3 ASCI 56 statin monotherapy 56 preoperative PSA 56 dalteparin 56 oestradiol 56 virologic failures 56 genotypic 56 g dL 56 tumor histology 56 NATRECOR ® 56 EGFR expression 56 lipid profiles 56 serum folate concentrations 56 boosted protease inhibitor 56 serum magnesium 56 anemia neutropenia 56 μg dose 56 serum triglyceride levels 56 CD4 CD8 56 Pioglitazone 56 systemic toxicity 56 REYATAZ r 56 saline placebo 56 SGOT 56 Betaferon ® 56 OGTT 56 antiangiogenic therapy 56 titers 56 VELCADE melphalan 56 Disease Progression 56 antibody responses 56 telomere lengths 56 blood phenylalanine Phe 56 inducible nitric oxide synthase 56 CK # plasma 56 DLTs 56 nanomolar 56 cerebral oxygen saturation 56 Natalizumab 56 palivizumab 56 bronchoalveolar lavage fluid 56 dose dexamethasone 55 HBeAg negative patients 55 g dl 55 bisoprolol 55 statistically significant p = 55 azacitidine 55 plasma homocysteine 55 periprocedural MI 55 antioxidant supplementation 55 splenectomized patients 55 MADRS score 55 Fasting plasma glucose 55 apo B apo AI 55 hENT1 55 ± SD 55 Mg Uk 55 estimated GFR 55 serum bilirubin 55 acromegalic patients 55 eplerenone 55 ApoA1 55 nonpregnant women 55 bronchodilation 55 hepatic insulin sensitivity 55 IUGR 55 Solid Tumors criteria 55 lupus anticoagulant 55 vasopressor 55 response CCyR 55 Nilotinib 55 Crohn Disease Activity 55 dosage regimens 55 statistical significance p 55 #.#mg/dL 55 peg interferon 55 hydroxy vitamin D 55 Tekamlo 55 plasma viremia 55 hypertensives 55 intracranial hemorrhage ICH 55 prednisone prednisolone 55 dose dependently 55 hMG 55 femoral neck BMD 55 Lp PLA2 55 Platelet counts 55 gonadotropin releasing hormone 55 metastatic GIST 55 seropositivity 55 abdominal adiposity 55 HDRS 55 isoenzyme 55 androgen deprivation 55 HbA1c 55 colorectal adenoma 55 hepatic glucose production 55 mmHg diastolic 55 lipid lowering drugs 55 adiponectin levels 55 adjunctive ABILIFY 55 bioavailable testosterone 55 CHD mortality 55 bone marrow reticulin 55 microalbumin 55 adalimumab 55 oral antidiabetic medication 55 μg liter 55 GnRH agonists 55 microg 55 ApoB 55 IgG antibody 55 NAbs 55 mitoxantrone 55 poor metabolizers 55 atorvastatin #mg 55 dexmedetomidine 55 low dose ritonavir 55 peginterferon 55 estramustine 55 Calcium intake 55 insulin degludec 55 peak plasma concentrations 55 avosentan 55 IDDM 55 systolic BP 55 intravenous CK # 55 IFN beta 55 ascending doses 55 isoproterenol 55 XIENCE V demonstrated 55 STRIDE PD 55 telomerase activity 55 HCV genotype 55 baseline Hb 55 DFMO 55 neurologic progression 55 Baseline characteristics 55 INCB# [001] 55 attain statistical significance 55 gastric pH 55 Pharmacokinetic 55 A1C levels 55 prostate carcinoma 55 fraction LVEF 55 nondiabetic patients 55 VIRAMUNE 55 Victoza R 55 urinary albumin excretion 55 ug dose 55 hemodialysis patients 55 dosing frequency 55 dose atorvastatin 55 virologically suppressed 55 pharmacokinetic interactions 55 microglial activation 55 COMBIVIR 55 Hgb 55 bolus injection 55 mcg Albuferon 55 biphasic insulin aspart 55 disease progression 55 NYHA functional class 55 ribavirin therapy 55 Proteinuria 55 partial remissions 55 sweat chloride 55 seminoma 55 atazanavir sulfate 55 anti Xa 55 SERCA2a 55 NRTI 55 tertile 55 CLA supplementation 55 plasma selenium 55 weekly subcutaneous injections 55 methotrexate monotherapy 55 protease inhibitors PIs 55 gonadotropins 55 SUVmax 55 cTnT 55 #mg QD [002] 55 SCr 55 adrenomedullin 55 operable breast cancer 55 hemoglobin A1C 55 metabolic parameters 55 brachial artery flow 55 pimozide 55 hepatitis B immunoglobulin 55 Darunavir 55 CD4s 55 DMARD 55 unfractionated heparin UFH 55 p = #.# [003] 55 dose Iluvien 55 follicle stimulating hormone 55 Gleevec resistant 55 cTnI 55 LV dysfunction 55 Myelosuppression 55 Ramipril 55 somatostatin analogs 55 dexamethasone Decadron 55 urine NGAL 55 thromboembolic events 55 VIRAMUNE XR 55 nephrotoxicity 55 growth hormone secretion 55 CD8 T cell 55 Tipranavir 55 antigen PSA 55 NIH CPSI 55 natriuretic peptides 55 hip BMD 55 degarelix 55 peripheral blood mononuclear 55 efavirenz EFV 55 histologically confirmed 55 CIMZIA TM certolizumab pegol 55 thyroid stimulating hormone TSH 55 TMC# C# 55 systolic diastolic blood 55 mg/m2 cohort 55 pyridostigmine 55 potent antiretroviral therapy 55 urinary N telopeptide 55 FXIII 55 darunavir ritonavir 55 urinary cortisol 55 T2 lesions 55 virologically 55 lipid lowering therapy 55 immunoreactivity 55 ritonavir Norvir 55 imipenem 55 locoregional disease 55 #.#mmol L [002] 55 maximal doses 55 LDL Cholesterol 55 progression TTP 55 adrenocorticotropic hormone 55 ZD# [001] 55 testosterone supplementation 55 CC genotype 55 rt PA 55 IFN γ 55 pomalidomide 55 bosentan 55 perioperative complications 55 ABCB1 55 LDL cholesterol concentrations 55 p# Shc 55 radical prostatectomy RP 55 μg kg 55 ritonavir boosted lopinavir 55 IV bisphosphonates 55 myocardial reperfusion 55 multivariate Cox 55 nucleoside naive 55 rapid virologic response 55 E selectin 55 hypophosphatemia 55 serum TSH 55 demonstrated clinically meaningful 55 pharmacokinetics PK 55 fibrosis progression 55 EGFR TKI 55 REYATAZ ritonavir 55 melphalan prednisone 55 preintervention 55 Viread Emtriva Sustiva 55 triple nucleoside 55 heterozygotes 55 IFN alfa 55 atazanavir 55 ELBW infants 55 Vagifem 55 systolic hypertension 55 serum selenium 55 mm Hg diastolic 55 Fasting glucose 55 ng mL 55 lipid levels 55 macroalbuminuria 55 elevated serum creatinine 55 nitroprusside 55 chlorambucil 55 NNRTI 55 mL/min/#.# m2 54 overt nephropathy 54 normotensive 54 trimethoprim sulfamethoxazole 54 hematopoietic cancers 54 RBC transfusions 54 tibolone 54 serum thyroglobulin 54 treatment naive genotype 54 beta adrenergic receptor 54 PROSTVAC VF 54 Febrile neutropenia 54 #Gy 54 peginterferon alfa 54 Raltegravir 54 3TC lamivudine Epivir 54 #β estradiol 54 double blinded placebo 54 UACR 54 Neutropenia 54 CD4 + lymphocytes 54 telaprevir dosed 54 G CSF 54 daunorubicin 54 symptomatic intracranial hemorrhage 54 tenofovir emtricitabine 54 QTc prolongation 54 rtPA 54 subcutaneously administered 54 lopinavir ritonavir 54 inhibin B 54 deep venous thromboses 54 hsCRP 54 colorectal carcinoma 54 baseline serum creatinine 54 inhibitor RG# 54 intravenous diuretics 54 RBP4 54 apo B 54 virologic breakthrough 54 periprocedural 54 angiotensin converting enzyme inhibitors 54 mEq L 54 CRp 54 APTIVUS R 54 Sustained virologic response 54 YERVOY 54 ACCOMPLISH 54 Doxil ® 54 MCyR 54 foveal thickness 54 cardiac repolarization 54 thyroid hormone levels 54 fetuin 54 mediated immunity 54 DAS# [002] 54 immune reconstitution 54 alfa 2a 54 IL 1ß 54 hemagglutination inhibition

Back to home page